5-(4-bromophenyl)-1-methyl-1H-tetrazole | 69746-31-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-bromophenyl)-1-methyl-1H-tetrazole
• 英文别名: 1-methyl-5-(4-bromophenyl)tetrazole；5-(4-bromo-phenyl)-1-methyl-1H-tetrazole；1-Methyl-5-(p-bromphenyl)-tetrazol；1-Methyl-5-p-bromphenyl-tetrazol；1-Methyl-5-(4'-bromophenyl)tetrazole；5-(4-bromophenyl)-1-methyltetrazole
• CAS: 69746-31-2
• 化学式: C₈H₇BrN₄
• 分子量: 239.074
• InChiKey: GCCZIWYYHJTSQK-UHFFFAOYSA-N

物化性质

• 熔点：
  143-144 °C(Solv: ethanol (64-17-5); water (7732-18-5))
• 沸点：
  358.3±44.0 °C(Predicted)
• 密度：
  1.69±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(4-bromophenyl)-1-methyl-1H-tetrazole 在 palladium on activated charcoal palladium diacetate 、 氢气 、 sodium acetate 、 三苯基膦 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(1-Cyclohexylmethyl-4-phenyl-pyrrolidin-3-ylmethyl)-4-{3-[4-(1-methyl-1H-tetrazol-5-yl)-phenyl]-propyl}-piperidin-4-ol
  参考文献：
  名称：

  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity

  摘要：

  Incorporation of acidic functional groups into a lead CCR5 antagonist identified from a targeted combinatorial library resulted in compounds with enhanced anti-HIV-1 activity and attenuated L-type calcium channel affinity. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00605-4
• 作为产物：
  描述：

  5-(4-溴苯)-1H-四唑 在 三乙胺 、 硫酸二甲酯 作用下， 以 氯仿 为溶剂， 反应 4.0h， 生成 5-(4-bromophenyl)-1-methyl-1H-tetrazole 、 5-(4-bromophenyl)-2-methyl-2H-tetrazole
  参考文献：
  名称：

  Tetrazoles: LIV. Alkylation of 5-aryltetrazoles under microwave activation

  摘要：

  The application of microwave activation (MWA) to alkylation of 5-aryltetrazoles with dimethyl sulfate in organic solvents did not considerably affect the selectivity of the process compared to nonactivated procedure. A significant enhancement of the selectivity to the formation of N(2)-methyl-isomer occurred only in the alkylation in the dimethyl sulfate solution.

  DOI：

  10.1134/s1070428009050133

文献信息

• [EN] ANTHELMINTIC AGENTS AND THEIR USE<br/>[FR] AGENTS ANTHELMINTIQUES ET LEUR UTILISATION
  申请人：INTERVET INT BV

  公开号：WO2010115688A1

  公开（公告）日：2010-10-14

  This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

  这项发明涉及一般用作驱虫剂或作为制备驱虫剂的中间体的化合物和盐。这项发明还涉及制备这些化合物和盐的方法，包括这些化合物和盐的药物组合物和试剂盒，使用这些化合物和盐制备药物，以及将这些化合物和盐用于需要治疗的动物的治疗方法。
• [EN] OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS<br/>[FR] DERIVES D'OXAZOLIDINONE UTILISES COMME AGENTS ANTIMICROBIENS
  申请人：RANBAXY LAB LTD

  公开号：WO2006038100A1

  公开（公告）日：2006-04-13

  The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria, for example, multiple-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms, for example, Bacterioides spp. and Clostridia spp. species, and acid fast organisms, for example, Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.

  本发明涉及某些取代苯基噁唑烷酮以及其合成方法。本发明还涉及含有本发明化合物作为抗微生物药物的药物组合物。这些化合物是有用的抗微生物剂，对多种人类和兽医病原体有效，包括革兰氏阳性厌氧细菌，例如多重耐药葡萄球菌、链球菌和肠球菌，以及厌氧生物，例如Bacterioides属和Clostridia属物种，以及耐酸生物，例如结核分枝杆菌、埃维分枝杆菌和分枝杆菌属。
• Structure-Based Optimization of Pyridoxal 5′-Phosphate-Dependent Transaminase Enzyme (BioA) Inhibitors that Target Biotin Biosynthesis in <i>Mycobacterium tuberculosis</i>
  作者：Feng Liu、Surendra Dawadi、Kimberly M. Maize、Ran Dai、Sae Woong Park、Dirk Schnappinger、Barry C. Finzel、Courtney C. Aldrich

  DOI：10.1021/acs.jmedchem.7b00189

  日期：2017.7.13

  relationships (SAR) through the design, synthesis, and biological evaluation of a systematic series of analogues of the original hit using a structure-based drug design strategy, which was enabled by cocrystallization of several analogues with BioA. To confirm target engagement and discern analogues with off-target activity, each compound was evaluated against wild-type (WT) Mtb in biotin-free and -containing

  吡咯醛5'-磷酸（PLP）依赖性转氨酶BioA催化结核分枝杆菌（Mtb）中生物素生物合成的第二步，并且是细菌存活和体内持久性所必需的酶。含有N-芳基，N的有前途的BioA抑制剂6以前已通过基于靶标的全细胞筛选确定了'-苯甲酰基哌嗪支架。在这里，我们使用基于结构的药物设计策略，通过设计，合成和生物学评估原始命中的系统类似物系列，探索结构与活性之间的关系（SAR），该策略是通过将几种类似物与BioA共结晶而实现的。为了确认靶标参与并辨别具有脱靶活性的类似物，评估了每种化合物在无生物素和含培养基的培养基中以及在表达过少和过表达的BioA Mtb菌株中对野生型（WT）Mtb的能力。构象受限的导数36成为最强的K D类似物为76nm针对的bioA和1.7μM（0.6微克/毫升）对的最小抑制浓度的Mtb在无生物素培养基。
• NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Moon Ho-Sang

  公开号：US20100063041A1

  公开（公告）日：2010-03-11

  The present invention provides a novel phenylpropionic acid derivative and a PPAR-γ modulator comprising the same as an active ingredient. The phenylpropionic acid derivative of the present invention has modulatory action on function of PPAR-γ and then exhibits hypoglycemic, hypolipidemic and insulin resistance-reducing effects on PPAR-mediated diseases or disorders. Therefore, the present invention is prophylactically or therapeutically effective for diabetes and metabolic diseases.

  本发明提供了一种新型苯丙酸衍生物，以及包含该衍生物作为活性成分的PPAR-γ调节剂。本发明的苯丙酸衍生物对PPAR-γ的功能具有调节作用，从而在PPAR介导的疾病或紊乱中表现出降糖、降脂和减少胰岛素抵抗的效果。因此，本发明在预防或治疗糖尿病和代谢性疾病方面具有预防或治疗效果。
• ANTHELMINTIC AGENTS AND THEIR USE
  申请人：Chassaing Christophe Pierre Alain

  公开号：US20110319393A1

  公开（公告）日：2011-12-29

  This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

  本发明涉及化合物和盐，通常可用作驱虫剂或作为制备驱虫剂的中间体。本发明还涉及制备这些化合物和盐的过程，包括这些化合物和盐的药物组合物和试剂盒，使用这些化合物和盐制备药物，并将这些化合物和盐用于治疗需要治疗的动物的治疗方法。